Sign In
Buy MEIP
$3.07
+0 (+0%)
At Close: Dec 09, 2025
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmace
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
07:02pm, Thursday, 11'th May 2023
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to loss of $3.40 per share a year ago.
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
07:35pm, Thursday, 09'th Feb 2023
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript
09:00pm, Thursday, 08'th Sep 2022
MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2022 Results Conference Call September 8, 2022 5:00 PM ET Company Participants David Walsey - Senior Vice President and Corporate Affairs Dan Gold - President and Ch
Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List
08:34pm, Friday, 17'th Jun 2022 PennyStocks
Can these penny stocks continue to make gains
The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co
Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List
04:34pm, Friday, 17'th Jun 2022
Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
11:20pm, Thursday, 09'th Jun 2022 PennyStocks
Biotech penny stocks to watch in June.
The post Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
07:20pm, Thursday, 09'th Jun 2022
Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
09:35pm, Monday, 23'rd May 2022 Zacks Investment Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
06:49pm, Monday, 23'rd May 2022
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue Estimates
01:35pm, Monday, 16'th May 2022 Zacks Investment Research
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -8.33% and 9.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates
12:45pm, Friday, 13'th May 2022 Zacks Investment Research
InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
11:05pm, Tuesday, 10'th May 2022 Zacks Investment Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -164.71% and 96.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s
